PPT-Classification of Prostate Cancer Patients into Indolent and Aggressive Using Machine

Presented By Yashwanth Karthik Kumar Mamidi 1 Committee Members Dr Minhaz Zibran Dr Christopher M Summa MentorsSupervisors Dr Md Tamjidul Hoque Dr Chindo Hicks MS Thesis Defense Presentation. Essex Biomedical . Sciences Institute (EBSI) . Elena Klenova, University of Essex. the search for a magic molecule. Most Common Types of Cancers in Men. info.cancerresearchuk.org/.../males/index.htm. . Julian Mander . RPH Urology. Aurora, CO. Introduction and Current ADT Challenges. Greetings from Colorado. Disclosures Consultant: MDxHealth, Myriad and Genomic Health, . Speaker: Ferring, Bayer, and Myriad . Faculty. Thomas E. Keane, M.D. Medical College of South Carolina. 01/24/2012. Agenda. 0. Introduction of machine . learning. --Some clinical examples. Introduction . of classification. 1. Cross validation. 2. . Over-fitting. Feature (gene) selection. Performance assessment. CÉSAR DAVID VERA-DONOSO. Department. of . Urology. WHO IS IN THE LINE OF FIRE?. WE NEED TO COLLABORATE IN MANY FIELDS. WE NEED RELIABLE IMAGES TO TAKE DECISIONS. INCIDENCE. EUROPE. In Europe, . PCa. cancer. Khanmi. . Kasomva. ,. Ph.D. . Research . Scholar,. Biotechnology & Molecular Biology Unit, . ERI, . Loyola . College. Chennai, . Inida. .. . . . What we will be discussing about. 1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, et al. JAMA . Oncol. . 2015; 1(4): 505-27/ 2. . Droz. JP, et al. Lancet . Oncol. . 2014; 15(9): e404-14/ 3. . Cuzick. J, et al. Lancet . Investigations for Prostate cancer Presentation: Diagnosis: Risk stratification (Ref) : Low risk PSA 0, Gleason score 6 (ISUP 1), DRE showing cT1 - T2a Intermediate risk: PSA 10 - 20, Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced . CSPC. Supported by an educational grant from Astellas and Pfizer, Inc.. EPISODE 3. Cora N. Sternberg MD, FACP. Clinical Director, . Latest developments. . Prof.. . Neeraj Agarwal, MD. Director, Genitourinary Oncology Program, . Huntsman Cancer Institute, University of Utah, USA. MARCH 2022. PARPi. , poly-ADP ribose polymerase inhibitors. Foundation Medicine. ctDNA. is good information for somatic mutations in . mCRPC. when biopsy is not possible. lots of other data on the importance of CTCs as predictive. 93% concordance for BRCA1/2 for tissue and liquid biopsy – . Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. Session Objectives. Updates of the Status of Research Effort. Evaluation of Biomarker Development Status. Imaging and Urine Testing to Enhance Prostate Cancer Detection. Martin . Sanda. , M.D., Emory University. CVC. Er. . . Mohd. . Shah . Alam. Assistant Professor. Department of Computer Science & Engineering,. UIET, CSJM University, Kanpur. Agenda. What is Machine Learning?. How Machine learning . is differ from Traditional Programming?.